Akoya Biosciences, Inc. (NASDAQ:AKYA) Given Consensus Recommendation of "Hold" by Brokerages

Akoya Biosciences, Inc. (NASDAQ:AKYA - Get Free Report) has been given a consensus rating of "Hold" by the seven research firms that are currently covering the company, Marketbeat.com reports. Seven research analysts have rated the stock with a hold recommendation. The average twelve-month price objective among brokers that have covered the stock in the last year is $3.21.

Several equities analysts recently commented on AKYA shares. Stephens reissued an "equal weight" rating and issued a $1.80 target price (down previously from $3.50) on shares of Akoya Biosciences in a report on Tuesday, March 25th. Canaccord Genuity Group dropped their price objective on Akoya Biosciences from $3.50 to $1.80 and set a "hold" rating on the stock in a report on Tuesday, April 29th. Finally, Piper Sandler decreased their target price on Akoya Biosciences from $2.40 to $1.65 and set a "neutral" rating for the company in a research note on Monday, April 14th.

Institutional Trading of Akoya Biosciences

A number of large investors have recently made changes to their positions in AKYA. SG Americas Securities LLC acquired a new position in shares of Akoya Biosciences in the 4th quarter valued at $28,000. Barclays PLC increased its stake in shares of Akoya Biosciences by 320.9% during the third quarter. Barclays PLC now owns 39,472 shares of the company's stock worth $107,000 after acquiring an additional 30,095 shares during the period. Paragon Associates & Paragon Associates II Joint Venture raised its stake in shares of Akoya Biosciences by 1.4% during the 4th quarter. Paragon Associates & Paragon Associates II Joint Venture now owns 801,000 shares of the company's stock worth $1,834,000 after buying an additional 11,000 shares in the last quarter. JPMorgan Chase & Co. raised its position in Akoya Biosciences by 295.4% in the fourth quarter. JPMorgan Chase & Co. now owns 48,313 shares of the company's stock worth $111,000 after acquiring an additional 36,093 shares in the last quarter. Finally, Intech Investment Management LLC acquired a new stake in shares of Akoya Biosciences in the fourth quarter valued at about $27,000. 79.42% of the stock is owned by institutional investors and hedge funds.

Akoya Biosciences Stock Down 0.9 %

Shares of Akoya Biosciences stock traded down $0.01 on Friday, reaching $1.13. 36,989 shares of the company were exchanged, compared to its average volume of 508,889. The stock's 50 day moving average price is $1.34 and its 200-day moving average price is $2.11. The company has a debt-to-equity ratio of 5.62, a current ratio of 2.75 and a quick ratio of 1.85. Akoya Biosciences has a 1-year low of $1.01 and a 1-year high of $4.65. The company has a market cap of $56.36 million, a P/E ratio of -0.96 and a beta of 1.34.

Akoya Biosciences (NASDAQ:AKYA - Get Free Report) last posted its quarterly earnings results on Monday, March 17th. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.02). Akoya Biosciences had a negative return on equity of 162.99% and a negative net margin of 66.77%. The firm had revenue of $21.34 million for the quarter, compared to analyst estimates of $21.34 million. As a group, equities analysts forecast that Akoya Biosciences will post -0.96 EPS for the current year.

Akoya Biosciences Company Profile

Akoya Biosciences, Inc, a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow.